Introduction
CA 125 is an epithelial membrane antigen which is of value in monitoring patients with ovarian cancer':", With choriocarcinoma and teratoma, the initial level of human chorionic gonadotrophin and alphafetoprotein have been shown to correlate with survival, low levels being associated with good prognoaisv". The present study was carried out to assess whether the initial level of CA 125 is also correlated with survival in ovarian cancer.
Summary
CA 125 is an epithelial membrane marker which can be detected in the serum of patients with ovarian cancer and which may reflect tumour burden. In a group of 42 patients, the level of this marker has also been shown to be significantly related to survival.
Methods and results CA 125 was assayed in 42 patients with epithelial ovarian cancer using the Centocor CA 125 kit (CIS UK Ltd). The patients presented after surgical diagnosis and/or a debulking operation. Using an arbitrary level of 250 u/ml, it was found that 13 patients had more than this level on presentation and 29 patients showed lower values. Median follow up was 10 months. Life-table analysis showed that patients with the lower levels experienced significantly better survival than did those with the higher values ( Figure 1 ). Median survival for patients with CA 125 greater than 250 u/ml was 310days, but for values less than 250 ujml the projected probability of survival is 0.91. Logrank analysis shows a significant difference between the survival of these two groups (x2 =7.79, 1 d.f., P=0.003).
Discussion
These early results add to the evidence validating CA 125 as a marker for common epithelial cancer of the ovary. If this finding is confirmed, it may be possible to use the presentation marker level to stratify patients for treatment. Caution will be needed, however, in ascribing patients to a particular group on marker levels alone, as it has been found that 18% of patients (particularly those with mucinous tumours) do not show elevated CA 125 marker levels at any stage", 
